Carysil Limited: Monitoring Agency Report for Q4 FY26 Confirms No Material Deviation in Fund Utilization
Carysil Limited's Monitoring Agency Report for Q4 FY26 confirms no material deviation in the utilization of ₹125 crore QIP funds. ₹87.86 crore has been utilized, with ₹33.79 crore remaining for capital expenditure. The report by ICRA Limited, dated May 8, 2026, covers the period ending March 31, 2026.
This is a routine regulatory filing confirming the utilization of previously raised funds. It does not introduce new significant financial information or strategic changes that would materially impact the company's stock.
The report indicates no material deviation in fund utilization, which is a neutral outcome. It confirms compliance with regulatory requirements.
Carysil Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026, as required by SEBI regulations. The report, issued by ICRA Limited, indicates that the utilization of funds raised through the Qualified Institutions Placement (QIP) is in line with the objects of the issue, with no material deviation observed.
The QIP, which opened on July 1, 2024, and closed on July 3, 2024, raised ₹125.00 crore. The net proceeds were ₹121.70 crore, later revised to ₹121.65 crore due to a minor increase in issue-related expenses.
Of the total net proceeds, ₹87.86 crore had been utilized by March 31, 2026. This includes ₹28.71 crore for funding capital expenditure towards procurement and installation of machines, equipment, and moulds for new manufacturing facilities, ₹31.25 crore for working capital requirements, and ₹27.90 crore for general corporate purposes. A total of ₹33.79 crore remained unutilized as of the end of the quarter, primarily for capital expenditure, with an expected utilization by March 31, 2027. The unutilized funds are currently invested in fixed deposits with HDFC Bank, earning an average interest rate of approximately 6.25% to 6.35%.
ICRA Limited confirmed that all utilization is as per the disclosures in the Offer Document, and there have been no material deviations requiring shareholder approval. The report also noted that the company has obtained all necessary government and statutory approvals and that arrangements for technical assistance are in operation.
What to do with a filing like this
CARYSIL LIMITED filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CARYSIL LIMITED. Read the original for the full detail.